"Ophthalmic Lenses And Methods For Correcting, Slowing, Reducing, And/Or Controlling The Progression Of Myopia In Conjunction With Use Of Atropine Or Related Compounds" in Patent Application Approval Process (USPTO 20240139026).

A patent application has been filed for ophthalmic lenses and methods that aim to correct myopia and slow its progression using atropine or related compounds. Myopia, or shortsightedness, is a condition where distant objects appear blurry. While current optical correction strategies can shift the image to the retina, they may not slow eye growth and the progression of myopia. Atropine eye drops have shown promise in slowing myopia progression, but higher concentrations can cause side effects. The patent application describes lenses that not only correct refractive errors but also help slow myopia progression and reduce visual disturbances. These lenses may incorporate features based on the concentration of atropine or related compounds used. [Extracted from the article]